Anthony J Saporita1, Junkui Ai, Zhou Wang. 1. Department of Urology, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Abstract
BACKGROUND: Androgen receptor (AR) is the key molecule in androgen-refractory prostate cancer. Despite androgen ablative conditions, AR remains active and is necessary for the growth of androgen-refractory prostate cancer cells. Nuclear localization of AR is a prerequisite for its transcriptional activation. We examined AR localization in androgen-dependent and androgen-refractory prostate cancer cells. METHODS AND RESULTS: We demonstrate increased nuclear localization of a GFP-tagged AR in the absence of hormone in androgen-refractory C4-2 cells compared to parental androgen-sensitive human prostate cancer LNCaP cells. Analysis of AR mutants impaired in ligand-binding indicates that the nuclear localization of AR in C4-2 cells is truly androgen-independent. The hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), inhibits basal PSA expression and disrupts the ligand-independent nuclear localization of AR at doses much lower than required to inhibit androgen-induced nuclear import. CONCLUSIONS: Hsp90 is a key regulator of ligand-independent nuclear localization and activation of AR in androgen-refractory prostate cancer cells.
BACKGROUND:Androgen receptor (AR) is the key molecule in androgen-refractory prostate cancer. Despite androgen ablative conditions, AR remains active and is necessary for the growth of androgen-refractory prostate cancer cells. Nuclear localization of AR is a prerequisite for its transcriptional activation. We examined AR localization in androgen-dependent and androgen-refractory prostate cancer cells. METHODS AND RESULTS: We demonstrate increased nuclear localization of a GFP-tagged AR in the absence of hormone in androgen-refractory C4-2 cells compared to parental androgen-sensitive humanprostate cancer LNCaP cells. Analysis of AR mutants impaired in ligand-binding indicates that the nuclear localization of AR in C4-2 cells is truly androgen-independent. The hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), inhibits basal PSA expression and disrupts the ligand-independent nuclear localization of AR at doses much lower than required to inhibit androgen-induced nuclear import. CONCLUSIONS:Hsp90 is a key regulator of ligand-independent nuclear localization and activation of AR in androgen-refractory prostate cancer cells.
Authors: Irina U Agoulnik; Ajula Vaid; William E Bingman; Halime Erdeme; Anna Frolov; Carolyn L Smith; Gustavo Ayala; Michael M Ittmann; Nancy L Weigel Journal: Cancer Res Date: 2005-09-01 Impact factor: 12.701
Authors: A Gotoh; S C Ko; T Shirakawa; J Cheon; C Kao; T Miyamoto; T A Gardner; L J Ho; C B Cleutjens; J Trapman; F L Graham; L W Chung Journal: J Urol Date: 1998-07 Impact factor: 7.450
Authors: Francois Lamoureux; Christian Thomas; Min-Jean Yin; Hidetoshi Kuruma; Ladan Fazli; Martin E Gleave; Amina Zoubeidi Journal: Clin Cancer Res Date: 2011-02-24 Impact factor: 12.531
Authors: Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston Journal: Assay Drug Dev Technol Date: 2016-09-08 Impact factor: 1.738
Authors: Mahesh Alur; Minh M Nguyen; Scott E Eggener; Feng Jiang; Soheil S Dadras; Jeffrey Stern; Simon Kimm; Kim Roehl; James Kozlowski; Michael Pins; Marek Michalak; Rajiv Dhir; Zhou Wang Journal: Am J Pathol Date: 2009-07-16 Impact factor: 4.307
Authors: Paul A Johnston; Minh M Nguyen; Javid A Dar; Junkui Ai; Yujuan Wang; Khalid Z Masoodi; Tongying Shun; Sunita Shinde; Daniel P Camarco; Yun Hua; Donna M Huryn; Gabriela Mustata Wilson; John S Lazo; Joel B Nelson; Peter Wipf; Zhou Wang Journal: Assay Drug Dev Technol Date: 2016-05 Impact factor: 1.738